CNBC July 24, 2024
Key Points
– Pfizer said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a potential approval.
– The hemophilia A treatment could become the company’s second gene therapy to enter the U.S. market after Beqvez, which was cleared in April for hemophilia B.
– Pfizer is among several drugmakers to invest in the rapidly growing field of gene and cell therapies — one-time, high-cost treatments that target a patient’s genetic source or cell to cure or significantly alter the course of a disease.
Pfizer on Wednesday said its experimental gene therapy for a rare genetic blood-clotting disorder succeeded in a large late-stage trial, paving the way for a...